Psoriasin In-shower Treatment
Coal Tar
Alva-amco Pharmacal Companies, Llc
Human Otc Drug
NDC 52389-670Psoriasin In-shower Treatment also known as Coal Tar is a human otc drug labeled by 'Alva-amco Pharmacal Companies, Llc'. National Drug Code (NDC) number for Psoriasin In-shower Treatment is 52389-670. This drug is available in dosage form of Lotion/shampoo. The names of the active, medicinal ingredients in Psoriasin In-shower Treatment drug includes Coal Tar - 20 mg/g . The currest status of Psoriasin In-shower Treatment drug is Active.
Drug Information:
| Drug NDC: | 52389-670 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Psoriasin In-shower Treatment |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Proprietary Name Base: | Psoriasin In-shower |
| The base of the Brand/Proprietary name excluding its suffix. |
| Proprietary Name Suffix: | Treatment |
| A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Coal Tar |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Alva-amco Pharmacal Companies, Llc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Lotion/shampoo |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | COAL TAR - 20 mg/g
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 03 Mar, 2021 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 21 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | M032 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Alva-Amco Pharmacal Companies, LLC
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 413306
2532521
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UPC: | 0072959010706
|
| UPC stands for Universal Product Code. |
| UNII: | R533ESO2EC
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 52389-670-05 | 140 g in 1 TUBE (52389-670-05) | 03 Mar, 2021 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose psoriasis / seborrheic dermatitis treatment
Product Elements:
Psoriasin in-shower treatment coal tar alcohol glycerin water aloe vera leaf polysorbate 80 cetearyl behenate anhydrous citric acid stearyl alcohol coal tar coal tar aloe vera leaf polysaccharides caprylic/capric/linoleic triglyceride glyceryl stearate se almond oil lavender oil myristyl alcohol oatmeal olive oil peg-100 stearate white petrolatum phenoxyethanol sheanut oil
Indications and Usage:
Uses for the relief of symptoms of psoriasis and/or seborrheic dermatitis including itching, scaling, flaking, redness and irriation of the skin. helps prevent recurrence.
Warnings:
Warnings for external use only.
When Using:
When using this product avoid contact with the eyes. if contact occurs rinse thoroughly with water.
Dosage and Administration:
Directions after cleansing, apply psoriasin in-shower treatment to affected areas on body and scalp. avoid applying to bottom of feet. leave on for at least 2 minutes, then rinse off and gently towel dry. for best results, use at least twice a week or as directed by a doctor. the active ingredient, coal tar, in psoriasin may affect very light hair color; test first on a few strands of hair before broader application to areas where light-colored hair is present. for use by normally healthy adults only; persons under 18 years of age or those with highly sensitive or allergic skin should use only as idrected by a doctor.
Stop Use:
Stop use and ask a doctor if condition worsens condition does not improve after regular use of this product as directed.
Information for Patients:
Other information you may report serious side effects to the phone number provided under questions? below.
Package Label Principal Display Panel:
Psoriasinshowerpdp
Further Questions:
Questions? 1-800-792-2582